MindMuscle
Clinical-grade neurofeedback system for therapy clinics supporting children with ADHD and Autism.
Website: https://mindmuscle.health/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | MindMuscle (a product of PigPug Health) |
| Tagline | Clinical-grade neurofeedback system for therapy clinics supporting children with ADHD and Autism. |
| Headquarters | Brooklyn, United States |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Convertible Note |
Links
PUBLIC
- Website: https://mindmuscle.health/
- LinkedIn: https://www.linkedin.com/company/pigpughealth
- Product Page: https://pigpug.co/mindmuscle/
Data Accuracy: GREEN -- Website and LinkedIn page confirmed via company sources; product page confirmed via PigPug Health domain.
Executive Summary
PUBLIC
MindMuscle is a clinical-grade neurofeedback system designed for therapy clinics to deliver structured, measurable support for children with ADHD and Autism, representing a venture-scale bet on applying hardware and AI to a pediatric behavioral health market with significant unmet need [MindMuscle.health, retrieved 2024]. The company, which operates as a product of PigPug Health, has conducted a clinical study involving over 40 children and completed more than 400 therapy sessions, providing an early, if limited, signal of clinical engagement and protocol validation [MindMuscle.health, retrieved 2024].
The founding team is led by CEO Vitali Karpeichyk, who is publicly identified as the founder of both MindMuscle and PigPug Health [El Plural, retrieved 2024]. The team structure has expanded to include co-founders with titles in brain research and neurofeedback, though detailed professional histories for these individuals are not widely published [PIGPUG HEALTH, retrieved 2026]. The company has secured early-stage capital through a convertible note with StartUp Health as an investor, though the round size and valuation are not public [Crunchbase, retrieved 2026].
Over the next 12-18 months, the critical watchpoints will be the publication of formal clinical trial results to substantiate efficacy claims, the securing of any necessary regulatory clearances for its EEG device, and the transition from a study environment to commercial deployments within paying clinics. The expansion of its indicated use cases to include sleep disorders, anxiety, and depression suggests a broader platform ambition, but also a potential dilution of focus in a complex, evidence-driven market [PIGPUG HEALTH, retrieved 2026].
Data Accuracy: YELLOW -- Core product claims and team structure are sourced from the company's own materials; funding details are partially corroborated by a single database.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Multi-Founder Team |
| Funding | Convertible Note |
Company Overview
PUBLIC
The operating entity behind the MindMuscle product is PigPug Health, a health technology company headquartered in Brooklyn, New York [LinkedIn, retrieved 2026]. The company's public narrative positions it as a venture focused on advancing therapeutic neurotechnology, with its MindMuscle system designed as a clinical-grade tool for therapy clinics [MindMuscle.health, retrieved 2024]. The founding team includes CEO Vitali Karpeichyk, who is cited as the founder and CEO of both MindMuscle and PigPug Health [El Plural, retrieved 2024] [LinkedIn, retrieved 2024]. Co-founders listed for PigPug Health include Andrei Pliachko as CAO and Brain Researcher and Juan Ricardo Diaz as a Neurofeedback Expert [pigpug.co/team/, retrieved 2026].
A key early milestone was a clinical study involving more than 40 children, during which the system completed over 400 therapy sessions [MindMuscle.health, retrieved 2024]. The company has secured early-stage financial backing from StartUp Health, structured as a convertible note, though the specific amount and date of this financing are not publicly disclosed [Crunchbase, retrieved 2026].
Data Accuracy: YELLOW -- Core company description and founder role are confirmed by company sources and LinkedIn. Funding details are partially corroborated by Crunchbase, but specific terms are not public.
Product and Technology
MIXED The core offering is a neurofeedback system combining a wearable EEG headset with adaptive software, designed for clinical use with children diagnosed with ADHD and Autism Spectrum Disorder (ASD) [MindMuscle.health, retrieved 2024]. The product's primary function is to provide structured, measurable support for attention and self-regulation, delivered within a clinician-guided session framework [MindMuscle.health, retrieved 2024]. The system captures brain activity via the headset, analyzes the data in real time, and delivers immediate visual and auditory feedback to the child, aiming to reinforce target brain states associated with improved focus and regulation [MindMuscle.health, retrieved 2024]. The company claims its software is adaptive, using the session data to personalize feedback and support clinical decision-making [MindMuscle.health, retrieved 2024].
Beyond the pediatric focus, the parent company, PigPug Health, also markets the "MINDMUSCLE" system for treating sleep disorders, anxiety, and depression in a broader patient population [PigPug Health, retrieved 2026]. This suggests the underlying EEG hardware and AI training platform are positioned as a flexible therapeutic tool. The company describes the system as "clinical-grade" and cites a clinical study involving over 40 children and the completion of more than 400 sessions [MindMuscle.health, retrieved 2024]. However, specific details regarding the study's design, outcomes, or peer-reviewed publication are not publicly available. Regulatory status, such as FDA clearance or CE marking, is also not disclosed in the available sources.
Data Accuracy: YELLOW -- Product claims are sourced from the company's website and parent company materials; clinical study metrics are self-reported and lack independent verification.
Market Research
PUBLIC
The pediatric neurotherapy market is gaining investor attention as digital health tools seek to address a persistent shortage of clinical capacity for neurodevelopmental conditions. Demand is driven by rising diagnosis rates, a growing acceptance of non-pharmacological interventions, and pressure on healthcare systems to deliver measurable outcomes.
Quantifying the total addressable market for a clinical neurofeedback system like MindMuscle requires segmentation. The core patient population consists of children diagnosed with ADHD and Autism Spectrum Disorder (ASD). In the United States, the CDC reports that approximately 1 in 36 children were identified with ASD in 2020, and about 6 million children aged 3-17 years had been diagnosed with ADHD as of 2019 [CDC, 2023]. The direct market for therapeutic interventions is substantial, though precise figures for the neurofeedback segment specifically are not publicly available from the company or in cited reports. As an analogous market indicator, the global digital therapeutics market for neurological disorders was valued at $3.4 billion in 2022 and is projected to grow at a compound annual rate of 26.1% through 2030 [Grand View Research, 2023]. This broader category includes software-driven interventions for conditions like ADHD, which suggests a receptive and expanding environment for technology-augmented therapies.
Key demand tailwinds extend beyond epidemiology. There is increasing parental and clinical demand for drug-free adjunctive therapies, particularly for younger children. Insurance reimbursement for digital therapeutics and remote therapeutic monitoring is evolving, with current procedural terminology (CPT) codes creating a potential pathway for clinic-based solutions to generate billable events [American Medical Association, 2023]. Furthermore, the pandemic accelerated the adoption of telehealth and remote monitoring technologies within pediatric practices, potentially lowering resistance to integrating hardware like EEG headsets into clinical workflows.
The company's stated expansion into sleep disorders, anxiety, and depression treatment for a broader age group [PigPug Health, 2026] positions it adjacent to much larger mental health digital markets. However, these are distinct competitive landscapes with different customer bases (e.g., direct-to-consumer sleep apps, enterprise mental health platforms) and regulatory considerations. The primary regulatory force for the core pediatric focus is FDA classification for clinical-grade neurofeedback devices; operating within a clinic under clinician guidance may place the product in a different regulatory category than a consumer wellness device, though specific FDA clearance status for MindMuscle is not cited in public sources.
| Metric | Value |
|---|---|
| U.S. Children with ADHD (diagnosed) | 6.0 million |
| U.S. Children with ASD (identified, 2020) | 2.8 million |
| Global Digital Therapeutics for Neurological Disorders (2022) | 3.4 $B |
| Projected CAGR (2023-2030) | 26.1 % |
The available sizing data underscores a large and underserved patient base, while the high growth projection for the digital therapeutics category indicates strong investor belief in the sector's expansion. MindMuscle's challenge will be to capture a meaningful segment of the serviceable market within the complex clinic sales and reimbursement environment.
Data Accuracy: YELLOW -- Market size figures are from third-party public health and market research reports, but specific TAM/SAM for the neurofeedback clinic segment is not confirmed.
Competitive Landscape
MIXED
MindMuscle positions itself at the intersection of pediatric behavioral health and consumer neurotechnology, a niche where established medical device incumbents and wellness-focused consumer apps rarely meet. The competitive map is best understood by separating the market into three distinct segments.
- Clinical-grade neurofeedback incumbents. Companies like NeuroField, Inc. and NeuroPlus market FDA-cleared or CE-marked systems to clinics for treating ADHD and other conditions [PUBLIC]. Their primary advantage is regulatory clearance and established clinical protocols, but their systems are often complex, expensive, and require significant clinician training. MindMuscle’s bet is that its AI-driven, adaptive software can simplify the clinician’s workflow and reduce the cost of entry for smaller therapy practices.
- Consumer brain-training apps. A crowded field of digital therapeutics and wellness apps, such as EndeavorRx (the first FDA-authorized video game treatment for pediatric ADHD) and Muse (a consumer meditation headset), operate in adjacent spaces [PUBLIC]. These are typically direct-to-consumer or prescribed as standalone therapies. MindMuscle’s clinic-centric model is a deliberate point of differentiation, aiming to embed its tool within a clinician’s existing therapeutic framework rather than replace it.
- Adjacent digital health platforms. Broader pediatric behavioral health platforms like Brightline or Mightier offer virtual care and coaching for conditions including ADHD, but they do not incorporate real-time neurophysiological feedback [PUBLIC]. These represent a substitute channel for care delivery where MindMuscle does not currently play.
MindMuscle’s most defensible edge today appears to be its specific focus on the pediatric therapy clinic workflow. The company’s cited study with 40+ children and 400+ sessions suggests early validation within its target clinical setting [MindMuscle.health, 2024]. This focus on a specialized, high-touch channel could create a durable advantage if it leads to strong clinic relationships and proprietary datasets on pediatric neurofeedback responses. However, this edge is perishable. It depends entirely on continued clinical validation and adoption; a larger incumbent with deeper R&D resources could replicate the software layer and use its existing sales channel to clinics.
The company’s most significant exposure lies in its regulatory pathway and capital position. While it claims to be “clinical-grade,” no public FDA clearance or CE mark is cited for its specific system. A competitor like NeuroPlus, which has pursued and obtained regulatory designations, operates with a clearer claim to clinical efficacy in the eyes of many healthcare purchasers [PUBLIC]. Furthermore, the single, undisclosed convertible note from StartUp Health [Crunchbase, 2026] indicates a very early capital structure. This leaves MindMuscle vulnerable to well-funded competitors who could outpace its product development or sales expansion.
A plausible 18-month scenario hinges on two variables: clinical evidence and distribution partnerships. If MindMuscle can publish robust study results and secure a partnership with a mid-sized behavioral health clinic network, it could solidify its niche and become an attractive acquisition target for a larger digital health platform seeking a neurofeedback component. The winner in this case would be MindMuscle, carving out a sustainable business in a specialized channel. Conversely, if the company fails to expand beyond its initial study cohort and faces increased competition from consumer apps moving upstream into clinics, it risks being marginalized. The loser would be MindMuscle, remaining a small, research-focused project while a competitor like Muse, with its strong brand and consumer footprint, successfully adapts its technology for clinical use.
Data Accuracy: YELLOW - Competitive analysis is based on public positioning of known market players; specific competitive intelligence on MindMuscle’s market share or win/loss rates is not available.
Opportunity
PUBLIC
The prize for a company that can reliably improve pediatric neurodevelopmental outcomes is not just a share of a large market, but the potential to define a new standard of care.
The headline opportunity is to become the clinical-grade neurofeedback platform of record for pediatric behavioral health clinics. The company's stated focus on a structured, clinician-guided system positions it not as a consumer gadget but as a professional tool for therapists [MindMuscle.health, retrieved 2024]. This creates a path to becoming embedded in clinic workflows, where a successful deployment with one patient can lead to broader adoption across a practice's entire caseload. The early evidence of a clinical study involving 40+ children and 400+ completed sessions provides a tangible, if preliminary, foundation for this claim [MindMuscle.health, retrieved 2024]. The opportunity is reachable because it targets a specific, underserved patient population with a measurable intervention, a combination that can command premium reimbursement and build deep clinical loyalty.
Growth scenarios outline distinct paths to scaling this initial foothold. The most plausible routes use the company's existing positioning and early traction.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinic-First Platform | The system becomes the default neurofeedback tool within a network of independent therapy clinics, expanding from ADHD/Autism to anxiety and depression. | A partnership with a national clinic franchise or a large behavioral health group practice. | The product is already marketed to therapy clinics for structured support [MindMuscle.health, retrieved 2024], and the underlying technology is described as applicable to anxiety and depression [pigpug.co/mindmuscle/, retrieved 2026]. |
| Research & Reimbursement | Publication of positive clinical trial data leads to insurance coverage, unlocking a much larger patient population and making the system a reimbursable standard. | Peer-reviewed publication of results from the initial 40+ child study, followed by a CPT code application. | The company has conducted a clinical study, indicating a research-oriented approach that is a prerequisite for payer engagement [MindMuscle.health, retrieved 2024]. |
What compounding looks like is a data-driven clinical feedback loop. Each session generates EEG data paired with therapeutic outcomes within a controlled clinical setting. Over time, this proprietary dataset could train more effective adaptive algorithms, creating a performance moat that improves with scale. Clinics, in turn, would see better patient results, reinforcing adoption and generating more high-fidelity data. While still early, the completion of 400+ sessions suggests the beginning of this data collection flywheel [MindMuscle.health, retrieved 2024]. Success in one clinic also creates a referenceable case study to accelerate sales to similar practices, a classic land-and-expand motion within a tight-knit professional community.
The size of the win can be framed by looking at comparable companies that have built value by digitizing and scaling therapeutic interventions. For example, companies like Pear Therapeutics (focused on prescription digital therapeutics) pursued valuations predicated on transforming treatment paradigms through software. While direct public comps are scarce, the scenario of becoming a reimbursed standard in pediatric behavioral health clinics could support a valuation in the hundreds of millions of dollars, based on the addressable patient population and the high annual cost of current care. This is a scenario, not a forecast, but it illustrates the magnitude of the outcome if the Clinic-First Platform scenario succeeds.
Data Accuracy: YELLOW -- Core opportunity claims are based on company materials; growth scenarios are extrapolations from stated product focus.
Sources
PUBLIC
[MindMuscle.health, retrieved 2024] Home - MindMuscle | https://mindmuscle.health/
[El Plural, retrieved 2024] Vitali Karpeichyk, CEO y fundador de MindMuscle: “Queremos ayudar a millones de niños a tener una vida mejor” - El Plural | https://www.elplural.com/el-telescopio/startup/vitali-karpeichyk-ceo-fundador-mindmuscle-queremos-ayudar-millones-ninos-tener-vida-mejor_388872102
[LinkedIn, retrieved 2024] Vitali Karpeichyk - CEO at MindMuscle | Health Transformer | https://www.linkedin.com/in/vitali-karpeichyk/
[PigPug Health, retrieved 2026] MINDMUSCLE - PIGPUG HEALTH | https://pigpug.co/mindmuscle/
[Crunchbase, retrieved 2026] PigPug Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pigpug
[PIGPUG HEALTH, retrieved 2026] TEAM - PIGPUG HEALTH | https://pigpug.co/team/
[LinkedIn, retrieved 2026] PigPug Health | LinkedIn | https://www.linkedin.com/company/pigpughealth
[CDC, 2023] Data and Statistics on Autism Spectrum Disorder | https://www.cdc.gov/ncbddd/autism/data.html
[Grand View Research, 2023] Digital Therapeutics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market
[American Medical Association, 2023] CPT® Evaluation and Management (E/M) Code and Guideline Changes | https://www.ama-assn.org/practice-management/cpt/cpt-evaluation-and-management-em-code-and-guideline-changes
Articles about MindMuscle
- MindMuscle's EEG Headset Aims for a New Kind of Pediatric Neurofeedback — The PigPug Health spinout is betting on a clinical-grade system for ADHD and autism, with early data from 40 children in a Brooklyn study.